Aldeyra Therapeutics, Inc. – NASDAQ:ALDX
Aldeyra Therapeutics stock price today
$5.516
+0.57
+11.66%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 10 hours
Aldeyra Therapeutics stock price monthly change
+27.98%
month
Aldeyra Therapeutics stock price quarterly change
+27.98%
quarter
Aldeyra Therapeutics stock price yearly change
+36.09%
year
Aldeyra Therapeutics key metrics
Market Cap | 281.69M |
Enterprise value | 478.50M |
P/E | -9.62 |
EV/Sales | N/A |
EV/EBITDA | -7.95 |
Price/Sales | N/A |
Price/Book | 4.01 |
PEG ratio | -10.29 |
EPS | -0.51 |
Revenue | N/A |
EBITDA | -31.34M |
Income | -30.00M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAldeyra Therapeutics stock price history
Aldeyra Therapeutics stock forecast
Aldeyra Therapeutics financial statements
| Jun 2023 | 0 | -8.98M | |
|---|---|---|---|
| Sep 2023 | 0 | -8.18M | |
| Dec 2023 | 392.62K | -4.75M | -1210.58% |
| Mar 2024 | 0 | -8.08M |
| Dec 2023 | 392.62K | -4.75M | -1210.58% |
|---|---|---|---|
| Mar 2024 | 0 | -8.08M | |
| Oct 2025 | 0 | -12.47M | |
| Dec 2025 | 0 | -12.47M |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 155616350 | 25.73M | 16.54% |
|---|---|---|---|
| Sep 2023 | 147282247 | 24.27M | 16.48% |
| Dec 2023 | 148326911 | 28.53M | 19.24% |
| Mar 2024 | 141301892 | 27.88M | 19.73% |
| Jun 2023 | -13.35M | 0 | 5.29K |
|---|---|---|---|
| Sep 2023 | -8.02M | 0 | -315.75K |
| Dec 2023 | 500.44K | 0 | -1.01M |
| Mar 2024 | -9.97M | -30.37M | 18.19K |
Aldeyra Therapeutics alternative data
| Aug 2023 | 15 |
|---|---|
| Sep 2023 | 15 |
| Oct 2023 | 15 |
| Nov 2023 | 15 |
| Dec 2023 | 12 |
| Jan 2024 | 12 |
| Feb 2024 | 12 |
| Mar 2024 | 10 |
| Apr 2024 | 10 |
| May 2024 | 10 |
| Jun 2024 | 10 |
| Jul 2024 | 10 |
Aldeyra Therapeutics other data
100.00%
0.00%
of ALDX is owned by hedge funds
98
-11
38.61M
+2.11M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Oct 2023 | 0 | 2756499 |
| Mar 2024 | 0 | 226207 |
| Apr 2024 | 682265 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | PERCEPTIVE ADVISORS LLC 10 percent owner | Common Stock | 37,712 | $4.74 | $178,755 | ||
Purchase | PERCEPTIVE ADVISORS LLC 10 percent owner | Common Stock | 140,281 | $4.67 | $655,112 | ||
Purchase | PERCEPTIVE ADVISORS LLC 10 percent owner | Common Stock | 309,847 | $4.09 | $1,267,274 | ||
Purchase | PERCEPTIVE ADVISORS LLC 10 percent owner | Common Stock | 186,051 | $3.44 | $640,015 | ||
Purchase | PERCEPTIVE ADVISORS LLC 10 percent owner | Common Stock | 8,374 | $3.25 | $27,216 | ||
Sale | MACHATHA STEPHEN officer: Chief Development Offi.. | Common Stock | 11,537 | $3.16 | $36,503 | ||
Sale | BRADY TODD C director, officer.. | Common Stock | 85,324 | $3.05 | $260,238 | ||
Sale | GREENBERG BRUCE officer: See Remarks | Common Stock | 13,201 | $3.41 | $44,963 | ||
Sale | MACHATHA STEPHEN officer: Chief Development Offi.. | Common Stock | 18,231 | $3.41 | $62,095 | ||
Sale | BRADY TODD C director, officer.. | Common Stock | 97,914 | $3.27 | $320,570 |
| Patent |
|---|
Application Filling date: 15 Mar 2022 Issue date: 7 Jul 2022 |
Application Filling date: 7 Mar 2022 Issue date: 30 Jun 2022 |
Application Filling date: 23 Sep 2021 Issue date: 16 Jun 2022 |
Application Filling date: 12 Oct 2021 Issue date: 5 May 2022 |
Application Filling date: 5 Dec 2019 Issue date: 5 May 2022 |
Application Filling date: 2 May 2020 Issue date: 24 Mar 2022 |
Application Filling date: 6 Aug 2019 Issue date: 20 Jan 2022 |
Application Filling date: 28 May 2021 Issue date: 23 Dec 2021 |
Application Filling date: 28 May 2021 Issue date: 23 Dec 2021 |
Grant Filling date: 25 Sep 2019 Issue date: 14 Dec 2021 |
| Quarter | Transcript |
|---|---|
| Q4 2022 9 Mar 2023 | Q4 2022 Earnings Call Transcript |
| Q3 2022 10 Nov 2022 | Q3 2022 Earnings Call Transcript |
| Q2 2022 5 Aug 2022 | Q2 2022 Earnings Call Transcript |
| Q1 2022 5 May 2022 | Q1 2022 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Dr. Todd C. Brady M.D., Ph.D. (1972) Chief Executive Officer, Pres & Director | $854,400 |
Mr. Joshua Reed M.B.A. (1973) Chief Financial Officer | $546,400 |
Aldeyra Therapeutics: A Mispriced Gem With Reproxalap's CRL Creating A Golden Buying Opportunity
After A CRL Setback, Aldeyra Therapeutics Is A Compelling Speculative Buy
Aldeyra Therapeutics: Key Inflection Point Ahead
Aldeyra: A Speculative Buy Amid Reproxalap's NDA Resubmission
Why Aldeyra Therapeutics Is A Strong Buy: AbbVie Agreement And Reproxalap's Prospects
Aldeyra:Upcoming PDUFA, Strong NDA, Long Pipeline, Decent Cash
Aldeyra Therapeutics: Navigating The Future Of Eye Disease Treatment With Reproxalap
Aldeyra Therapeutics: Navigating The Future Of Eye Disease Treatment With Reproxalap
Buy Aldeyra Therapeutics For Consecutive Runups
-
What's the price of Aldeyra Therapeutics stock today?
One share of Aldeyra Therapeutics stock can currently be purchased for approximately $5.52.
-
When is Aldeyra Therapeutics's next earnings date?
Unfortunately, Aldeyra Therapeutics's (ALDX) next earnings date is currently unknown.
-
Does Aldeyra Therapeutics pay dividends?
No, Aldeyra Therapeutics does not pay dividends.
-
How much money does Aldeyra Therapeutics make?
Aldeyra Therapeutics has a market capitalization of 281.69M.
-
What is Aldeyra Therapeutics's stock symbol?
Aldeyra Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "ALDX".
-
What is Aldeyra Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Aldeyra Therapeutics?
Shares of Aldeyra Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Aldeyra Therapeutics's key executives?
Aldeyra Therapeutics's management team includes the following people:
- Dr. Todd C. Brady M.D., Ph.D. Chief Executive Officer, Pres & Director(age: 53, pay: $854,400)
- Mr. Joshua Reed M.B.A. Chief Financial Officer(age: 52, pay: $546,400)
-
How many employees does Aldeyra Therapeutics have?
As Jul 2024, Aldeyra Therapeutics employs 10 workers.
-
When Aldeyra Therapeutics went public?
Aldeyra Therapeutics, Inc. is publicly traded company for more then 11 years since IPO on 2 May 2014.
-
What is Aldeyra Therapeutics's official website?
The official website for Aldeyra Therapeutics is aldeyra.com.
-
Where are Aldeyra Therapeutics's headquarters?
Aldeyra Therapeutics is headquartered at 131 Hartwell Avenue, Lexington, MA.
-
How can i contact Aldeyra Therapeutics?
Aldeyra Therapeutics's mailing address is 131 Hartwell Avenue, Lexington, MA and company can be reached via phone at +7 817614904.
Aldeyra Therapeutics company profile:
Aldeyra Therapeutics, Inc.
aldeyra.comExchange:
NASDAQ
Full time employees:
9
Industry:
Biotechnology
Sector:
Healthcare
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
131 Hartwell Avenue
Lexington, MA 02421
Lexington, MA 02421
CIK: 0001341235
ISIN: US01438T1060
CUSIP: 01438T106
